skip to the content

Avastin provides benefit in several tumour types

  • Clinical trials of Avastin in different tumour types have demonstrated that VEGF inhibition produces clinical benefit for the patient.
 
  • As a result, Avastin has been licensed
    • in Europe and the USA for use in the treatment of mCRC, mBC, unresectable advanced, metastatic or recurrent NSCLC and advanced and/or metastatic RCC5,6
    • in the USA for the treatment of GBM.6

First-line use of bevacizumab extends OS and/or PFS across multiple tumour types5,7–10

Efficacy across multiple tumor types